Abstract:Background Kinesin superfamily of proteins (KIFs) has been broadly reported to play an indispensable role in the biological process. Recently, emerging evidence reveals its oncogenic role in various cancers. However, the prognostic, oncological, and immunological values of KIFs have not been comprehensively explored in pancreatic ductal adenocarcinoma (PDAC) patients. We aimed to illustrate the relationship between KIFs and pancreatic ductal adenocarcinoma by using bioinformatical analysis. Methods We use GEPIA, Oncomine datasets, cBioPortal, LOGpc, TIMER, and STRING bioinformatics tools and web servers to investigate the aberrant expression, prognostic values, and oncogenic role of KIFs. The two-gene prognostic model and the correlation between KIFs and KRAS and TP53 mutation were performed using an R-based computational framework. Results Our results demonstrated that KIFC1/2C/4A/11/14/15/18A/18B/20B/23 (we name it prognosis-related KIFs) were upregulated and associated with unfavorable clinical outcome in pancreatic cancer patients. KIF21B overexpression is associated with better clinical outcome. The KIFC1/2C/4A/11/14/15/18A/18B/20B/23 profiles were significantly increased compared to grade 1 and grade 2/3. Besides, KIFC1/2C/4A/11/14/15/18A/18B/20B/23 was significantly associated with the mutation status of KRAS and TP53.Notably, most prognosis-related KIFs have strong correlations with tumor growth and myeloid-derived suppressor cells infiltration (MDSCs). A prognostic signature based on KIF20B and KIF21B showed a reliable predictive performance. Receiver operating characteristic (ROC) curve was employed to assess the predictive power of two-gene signature. Consequently, the gene set enrichment analysis (GSEA) showed that KIF20B and KIF21B’s overexpression was associated with the immunological and oncogenic pathway activation in pancreatic cancer. Finally, real-time quantitative PCR (RT-qPCR) was utilized to investigate the expression pattern of KIF20B and KIF21B in pancreatic cancer cell lines and normal pancreatic cell. Conclusions Knowledge of the expression level of the KIFs may provide novel therapeutic molecular targets and potential prognostic biomarkers to pancreatic cancer patients.

Characterization of KIF20B as a novel prognostic biomarker and therapeutic target for breast cancer

Overexpression of kinesin superfamily members as prognostic biomarkers of breast cancer

Identification of Novel Molecular Therapeutic Targets and Their Potential Prognostic Biomarkers Among Kinesin Superfamily of Proteins in Pancreatic Ductal Adenocarcinoma

An Integrated Bioinformatical Analysis to Evaluate the Role of KIF4A As a Prognostic Biomarker for Breast Cancer

High Expression of KIF26B in Breast Cancer Associates with Poor Prognosis.

An evaluation of KIF20A as a prognostic factor and therapeutic target for lung adenocarcinoma using integrated bioinformatics analysis

KIF23 is a potential biomarker of diffuse large B cell lymphoma Analysis based on bioinformatics and immunohistochemistry

Kinesin Family Member 23 Exerts a Protumor Function in Breast Cancer Via Stimulation of the Wnt/β-catenin Pathway

KIF15 Contributes to Cell Proliferation and Migration in Breast Cancer

KIF18B is a Prognostic Biomarker and Correlates with Immune Infiltrates in Pan-Cancer

Kif2a Silencing Inhibits the Proliferation and Migration of Breast Cancer Cells and Correlates with Unfavorable Prognosis in Breast Cancer

High Expression of KIF3A is a Potential New Parameter for the Diagnosis and Prognosis of Breast Cancer.

Identification of KIFC1 as an independent prognostic marker in renal clear cell carcinoma correlates with tumor proliferation and immune infiltration

High Expression of Kinesin KIF18B in Estrogen Receptor-Positive Breast Cancer Enhances Cell Proliferation and Apoptosis Resistance and Predicts Poor Prognosis

KIF20B Promotes Cell Proliferation and May Be a Potential Therapeutic Target in Pancreatic Cancer

Silencing of KIF18B Restricts Proliferation and Invasion and Enhances the Chemosensitivity of Breast Cancer Via Modulating Akt/GSK‐3β/β‐catenin Pathway

A pan-cancer exploration of kinesin family member 20A (KIF20A)'s oncogenic activity in human tumors

KIF11 As a Potential Pan-Cancer Immunological Biomarker Encompassing the Disease Staging, Prognoses, Tumor Microenvironment, and Therapeutic Responses

High Expression of KIF20A Is Associated with Poor Overall Survival and Tumor Progression in Early-Stage Cervical Squamous Cell Carcinoma

Expression, regulating mechanism and therapeutic target of KIF20A in multiple cancer

KIF20B Promotes the Progression of Clear Cell Renal Cell Carcinoma by Stimulating Cell Proliferation